

Stephen Salloway

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3655511/publications.pdf>

Version: 2024-02-01

103
papers

21,367
citations

71004

43
h-index

46524

93
g-index

123
all docs

123
docs citations

123
times ranked

24095
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 795-804.	13.9	3,005
2	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , The, 2014, 13, 614-629.	4.9	2,657
3	Alzheimer's disease. <i>Lancet</i> , The, 2016, 388, 505-517.	6.3	2,430
4	The antibody aducanumab reduces A β 2 plaques in Alzheimer's disease. <i>Nature</i> , 2016, 537, 50-56.	13.7	2,179
5	Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2014, 370, 322-333.	13.9	1,613
6	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.4	1,318
7	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. <i>Nature Medicine</i> , 2019, 25, 277-283.	15.2	610
8	Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2010, 3, 1.	3.0	424
9	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology</i> , The, 2021, 20, 484-496.	4.9	396
10	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. <i>Lancet Neurology</i> , The, 2012, 11, 241-249.	4.9	390
11	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. <i>Lancet Neurology</i> , The, 2018, 17, 241-250.	4.9	383
12	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. <i>Annals of Neurology</i> , 2016, 79, 929-939.	2.8	381
13	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2020, 26, 398-407.	15.2	351
14	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4502-9.	3.3	309
15	Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. <i>Brain</i> , 2017, 140, aww334.	3.7	257
16	Positron Emission Tomography Imaging With [¹⁸ F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. <i>JAMA Neurology</i> , 2020, 77, 829.	4.5	244
17	Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 13.	4.5	244
18	Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density. <i>JAMA Neurology</i> , 2015, 72, 287.	4.5	238

#	ARTICLE	IF	CITATIONS
19	Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 1002.	4.9	215
20	Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. <i>Clinical Therapeutics</i> , 2010, 32, 1234-1251.	1.1	194
21	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. <i>Neurology</i> , 2018, 91, e1295-e1306.	1.5	193
22	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	15.2	182
23	Developing an international network for Alzheimer's research: the Dominantly Inherited Alzheimer Network. <i>Clinical Investigation</i> , 2012, 2, 975-984.	0.0	180
24	Targeting Prodromal Alzheimer Disease With Avagacestat. <i>JAMA Neurology</i> , 2015, 72, 1324.	4.5	179
25	Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1505-1521.	0.4	163
26	A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. <i>Brain</i> , 2019, 142, 1723-1735.	3.7	156
27	Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 98.	3.0	152
28	Amyloid- β^{11} C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. <i>Neurology</i> , 2015, 85, 692-700.	1.5	136
29	Disease-modifying therapies in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2008, 4, 65-79.	0.4	132
30	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2018, 141, 3065-3080.	3.7	116
31	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1111.	4.5	112
32	Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). <i>Alzheimer's Research and Therapy</i> , 2018, 10, 96.	3.0	109
33	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 180-190.	1.2	84
34	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. <i>Brain</i> , 2018, 141, 1186-1200.	3.7	83
35	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. <i>Brain</i> , 2018, 141, 1486-1500.	3.7	79
36	<i>BDNF</i> Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. <i>Brain</i> , 2016, 139, 2766-2777.	3.7	70

#	ARTICLE	IF	CITATIONS
37	Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. <i>Brain</i> , 2015, 138, 1036-1045.	3.7	67
38	Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. <i>Brain</i> , 2021, 144, 2176-2185.	3.7	66
39	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 614-628.	4.1	61
40	Disruption of cholinergic neurotransmission exacerbates A β -related cognitive impairment in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2709-2715.	1.5	59
41	Performance of [¹⁸ F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA's recommendations for the neuropathologic diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 25-34.	1.2	57
42	Alzheimer disease: Time to improve its diagnosis and treatment. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, 49-58.	0.6	53
43	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1427-1437.	0.4	51
44	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. <i>PLoS ONE</i> , 2018, 13, e0195838.	1.1	51
45	Botulinum toxin for refractory vocal tics. <i>Movement Disorders</i> , 1996, 11, 746-748.	2.2	48
46	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine learning. <i>Alzheimer's and Dementia</i> , 2020, 16, 501-511.	0.4	47
47	Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 1197-1206.	0.4	45
48	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. <i>Nature Communications</i> , 2021, 12, 5346.	5.8	43
49	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 1225.	1.6	42
50	MRI subcortical hyperintensities in old and very old depressed outpatients. <i>Journal of the Neurological Sciences</i> , 2002, 203-204, 227-233.	0.3	37
51	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2019, 142, 1429-1440.	3.7	36
52	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. <i>Alzheimer's and Dementia</i> , 2020, 16, 1504-1514.	0.4	35
53	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 142, 104960.	2.1	31
54	Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. <i>Neurology</i> , 2018, 90, e877-e886.	1.5	28

#	ARTICLE	IF	CITATIONS
55	Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease. <i>Neurology</i> , 2021, 97, 543-544.	1.5	28
56	Microdosing of scopolamine as a "cognitive stress test": Rationale and test of a very low dose in an at-risk cohort of older adults. <i>Alzheimer's and Dementia</i> , 2014, 10, 262-267.	0.4	27
57	Seizures as an early symptom of autosomal dominant Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 76, 18-23.	1.5	27
58	Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 618-628.	0.4	27
59	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology</i> , The, 2021, 20, 615-626.	4.9	26
60	Effect of <i>BDNF</i> /Val66Met on disease markers in dominantly inherited Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 84, 424-435.	2.8	25
61	Subgroup Analysis of US and Non-US Patients in a Global Study of High-Dose Donepezil (23 mg) in Moderate and Severe Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2012, 27, 421-432.	0.9	23
62	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. <i>JAMA Network Open</i> , 2019, 2, e1917126.	2.8	23
63	Memory Processes in Depressed Geriatric Patients With and Without Subcortical Hyperintensities on MRI. <i>Journal of Neuroimaging</i> , 1998, 8, 20-26.	1.0	22
64	CADASIL Syndrome: A Genetic Form of Vascular Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1998, 11, 71-77.	1.2	21
65	Lowering the Floor on Trail Making Test Part B: Psychometric Evidence for a New Scoring Metric. <i>Archives of Clinical Neuropsychology</i> , 2015, 30, 643-656.	0.3	21
66	Infrequent false positive [18F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 60.	3.0	19
67	Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning. <i>Information Fusion</i> , 2020, 58, 153-167.	11.7	17
68	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1632-e1645.	1.5	16
69	The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients. <i>American Journal of Geriatric Psychiatry</i> , 2002, 10, 107-111.	0.6	16
70	Association of <i>BDNF</i> /Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 261.	4.5	15
71	Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnesic MCI. <i>International Psychogeriatrics</i> , 2008, 20, 40-46.	0.6	14
72	Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12199.	1.2	14

#	ARTICLE	IF	CITATIONS
73	Safety and Tolerability of Donepezil in Mild Cognitive Impairment: Open-Label Extension Study. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2010, 25, 155-159.	0.9	13
74	Understanding Conflicting Neuropathological Findings in Patients Clinically Diagnosed as Having Alzheimer Dementia. <i>JAMA Neurology</i> , 2015, 72, 1106.	4.5	13
75	Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study. <i>Current Alzheimer Research</i> , 2018, 15, 1231-1243.	0.7	13
76	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). <i>Alzheimer's and Dementia</i> , 2020, 16, 219-228.	0.4	13
77	Alzheimer's Disease in Primary Care: The Significance of Early Detection, Diagnosis, and Intervention. <i>American Journal of Medicine</i> , 2017, 130, 756.	0.6	12
78	Double blind randomized controlled trial of deep brain stimulation for obsessive-compulsive disorder: Clinical trial design. <i>Contemporary Clinical Trials Communications</i> , 2021, 22, 100785.	0.5	10
79	Current and Future Treatments for Alzheimer's Disease. <i>CNS Spectrums</i> , 2009, 14, 4-7.	0.7	8
80	U.S. POINTER (USA). <i>Alzheimer's and Dementia</i> , 2020, 16, e046951.	0.4	8
81	Putting the New Alzheimer Disease Amyloid, Tau, Neurodegeneration (AT[N]) Diagnostic System to the Test. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2289.	3.8	7
82	Machine Learning Classification Identifies Cerebellar Contributions to Early and Moderate Cognitive Decline in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 524024.	1.7	7
83	Dramatic neurobehavioral disorder in two cases following bilateral anteromedial frontal lobe injury: Delayed psychosis and marked change in personality. <i>Neurocase</i> , 1997, 3, 137-149.	0.2	6
84	Frontal Behavior Syndromes in Idiopathic Normal Pressure Hydrocephalus as a Function of Alzheimer's Disease Biomarker Status. <i>Journal of the International Neuropsychological Society</i> , 2020, 26, 883-893.	1.2	5
85	Differences in Burden Severity in Adult-Child Family Caregivers and Spousal Caregivers of Persons with Dementia. <i>Journal of Gerontological Social Work</i> , 2021, 64, 518-532.	0.6	4
86	Neuropsychiatric Factors in the Illusion of Visitors among Geriatric Patients: A Case Series. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1997, 10, 79-87.	1.2	3
87	Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention Trials. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	3
88	Are lobar microbleeds of diagnostic value in the community?. <i>Neurology</i> , 2019, 92, 121-122.	1.5	2
89	Clinical and pathological examples of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia. <i>Medicine and Health, Rhode Island</i> , 2012, 95, 207-9.	0.1	2
90	O1-03-02: Disruption of cholinergic neurotransmission unmasks Aβ-related cognitive impairment in preclinical Alzheimer's disease. , 2015, 11, P129-P130.		1

#	ARTICLE	IF	CITATIONS
91	[P2â€™047]: THE BUTLER ALZHEIMER'S PREVENTION REGISTRY: RECRUITMENT AND INTERIM OUTCOME. Alzheimer's and Dementia, 2017, 13, P622.	0.4	1
92	Combination therapy for Alzheimer's disease: Are we ready?. Alzheimer's and Dementia, 2018, 14, 1232-1233.	0.4	1
93	Dementia with Lewy bodies: a diagnostic and treatment challenge. Medicine and Health, Rhode Island, 2002, 85, 207-9.	0.1	1
94	O2-01-01: Plasma and Cerebrospinal Fluid Markers in the DIAN Study of Autosomal-Dominant Alzheimer's Disease. , 2011, 7, S287-S287.		0
95	IC-P-108: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION. , 2014, 10, P60-P61.		0
96	P2-202: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION. , 2014, 10, P546-P547.		0
97	FTS-03-03: THE DIAN-TU. , 2014, 10, P247-P247.		0
98	[O1â€™02â€™04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.4	0
99	P3â€™020: THE EFFECTS OF SUBJECTIVE COGNITIVE DECLINE ON APOE GENOTYPE DISCLOSURE IN THE BUTLER ALZHEIMER'S PREVENTION REGISTRY. Alzheimer's and Dementia, 2018, 14, P1071.	0.4	0
100	P1â€™132: DISRUPTION OF CHOLINERGIC NEUROTRANSMISSION, WITHIN A COGNITIVE CHALLENGE PARADIGM, PREDICTS AÎ²â€™RELATED COGNITIVE IMPAIRMENT IN PRECLINICAL ALZHEIMER'S DISEASE AFTER A 27â€™MONTH DELAY INTERVAL. Alzheimer's and Dementia, 2018, 14, P322.		0
101	P2â€™644: SAFETY, TOLERABILITY, AND LIFESTYLE CHANGES ASSOCIATED WITH APOE DISCLOSURE IN THE BUTLER ALZHEIMER'S PREVENTION REGISTRY: IMPLICATIONS FOR RECRUITMENT TO CLINICAL TRIALS. Alzheimer's and Dementia, 2018, 14, P989.	0.4	0
102	Dramatic Neurobehavioral Disorder in Two Cases Following Bilateral Anteromedial Frontal Lobe Injury: Delayed Psychosis and Marked Change in Personality. Neurocase, 1997, 3, 137-149.	0.2	0
103	Improving the diagnosis and treatment of Alzheimer's disease. Medicine and Health, Rhode Island, 2006, 89, 166-8.	0.1	0